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Adult T-cell leukemia/lymphoma (ATLL), an aggressive
neoplasm etiologically associated with human T-lymphotropic
virus type-1 (HTLV-1), is resistant to treatment. In this study, we
examined the effects of a new inhibitor of deacetylase enzymes,
LBH589, on ATLL cells. LBH589 effectively induced apoptosis
in ATLL-related cell lines and primary ATLL cells and reduced
the size of tumors inoculated in SCID mice. Analyses, including
with a DNA microarray, revealed that neither death receptors
nor p53 pathways contributed to the apoptosis. Instead,
LBH589 activated an intrinsic pathway through the activation
of caspase-2. Furthermore, small interfering RNA experiments
targeting caspase-2, caspase-9, RAIDD, p53-induced protein
with a death domain (PIDD) and RIPK1 (RIP) indicated that acti-
vation of RAIDD is crucial and an event initiating this pathway.
In addition, LBH589 caused a marked decrease in levels of
factors involved in ATLL cell proliferation and invasion such as
CCR4, IL-2R and HTLV-1 HBZ-SI, a spliced form of the HTLV-1
basic zipper factor HBZ. In conclusion, we showed that LBH589
is a strong inducer of apoptosis in ATLL cells and uncovered a
novel apoptotic pathway initiated by activation of RAIDD.
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Introduction
There is evidence that gene expression governed by epigenetic
changes is crucial to the pathogenesis of cancer.
1 Histone
deacetylases are enzymes involved in the remodeling of chroma-
tin, and have a key role in the epigenetic regulation of gene
expression. In addition, the activity of non-histone proteins can be
regulated through histone deacetylase-mediated hypoacetylation.
2
Deacetylase inhibitors (DACi) induce the hyperacetylation of non-
histone proteins, as well as nucleosomal histones resulting in the
expression of repressed genes involved in growth arrest, terminal
differentiation and/or apoptosis among cancer cells.
3,4 Several
classes of DACi have been found to have potent anticancer effects
in preclinical studies.
2 Despite a consensus on the importance of
apoptosis to the effect of these drugs, different apoptotic mecha-
nisms have been reported.
2 For instance, even the contribution of
caspases to DACi-induced apoptosis is quite controversial.
5–8
There are two general apoptotic pathways, the receptor
(extrinsic) pathway and the mitochondrial (intrinsic) pathway.
9
The extrinsic pathway requires activation of caspase-8, which
results in activation of the zymogens of executioner caspases such
as caspase-3, eventually leading to cleavage of poly ADP-ribose
polymerase (PARP). Proteolytic caspase-8 can further activate
BH3-interacting domain death agonist (BID), and cleaved BID
moves to the mitochondria where it triggers the release of
cytochrome-C. In the intrinsic pathway, death signals lead to
changes in the mitochondrial outer membrane’s permeability,
subsequently releasing cytochrome-C, which forms an apoptosome
with caspase-9, eventually activating executioner caspases.
10
LAQ824 and the more potent and newly developed
DACi analog LBH589 are now under clinical investigation as
a therapeutic agent for several kinds of cancer.
2,4 One unique
feature of these drugs is their role in the regulation of heat shock
protein 90kDa-a (HSP90) and degradation of HSP90 client
proteins such as bcr–abl in chronic myelogenous leukemia and
fms-related tyrosine kinase 3 in acute myeloid leukemia.
11–15
Adult T-cell leukemia/lymphoma (ATLL) is a neoplasm of
mature T-lymphocyte origin etiologically associated with human
T-lymphotropic virus type-1 (HTLV-1) and is known to be resistant
to standard anticancer therapies.
16 Previous ﬁndings suggest that
the viral protein HTLV-1 Tax interferes with most DNA repair
mechanisms, preventing cell cycle arrest and apoptosis, and
contributing to the early stages of ATLL.
17,18 In addition, the novel
viral protein HTLV-1 basic zipper factor (HBZ) and its spliced
form (HBZ SP1RNA or HBZ-SI), which are encoded by the minus-
strand RNA of the HTLV-1 genome, have been identiﬁed
recently.
19–23 These proteins are thought to be functional and
expected to be closely involved in the late stages of ATLL.
24 ATLL
is generally classiﬁed into four clinical subtypes: acute, chronic,
smoldering and lymphoma. Although several approaches have
been reported, combination chemotherapy is still the treatment of
choice for newly diagnosed acute and lymphoma-type ATLL.
Patients with aggressive ATLL have a median survival period of 13
months, indicating limitations in the treatment of ATLL.
25,26 In this
study, we examined the effects of LBH589 on ATLL cells in vitro
and in vivo, and investigated the pathways or factors contributing
to the LBH589-induced ATLL cell death.
Materials and methods
Cell preparation
The ATLL-derived cell lines ST1, KOB, LM-Y1, LM-Y2, KK1 and
SO4 were established in our laboratory from ATLL patients
27,28
and maintained in RPMI 1640 medium supplemented with
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www.nature.com/leu10% fetal bovine serum and 0.5U/ml of interleukin-2 (kindly
provided by Takeda Pharmaceutical Company, Ltd., Osaka,
Japan). The HTLV-1-infected T-cell lines MT2 and HuT102,
29,30
human T-cell leukemia cell line Jurkat and erythromyeloblastoid
cell line K562 were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum. The ST1, KOB,
LM-Y1, MT2 and HuT102 cells have the wild-type p53.
31
Primary leukemia cells from eight patients with acute-type ATLL
were also analyzed. The diagnosis of ATLL and preparation of
peripheral blood mononuclear cells from patients with ATLL
and normal healthy donors were described previously.
28 Each
patient’s sample contained more than 80% leukemia cells at
the time of analysis. After approval by the Ethics Committee
at Nagasaki University Hospital, all materials from patients
were obtained with informed consent.
Chemicals and cell proliferation assay
Chemicals used in this study were LBH589 (kindly provided by
Novartis Pharma AG., Basel, Switzerland), SAHA (Cayman
Chemical, Ann Arbor, MI, USA), MG132 (Biomol Research
Laboratories, Plymouth Meeting, PA, USA), LY294002 (Biomol),
soluble tumor necrosis factor related apoptosis-inducing ligand
(TRAIL) (Biomol), staurosporine (Merck, Darmstadt, Germany),
the pan-caspase inhibitor z-VAD-fmk, the caspase-2 inhibitor
Z-VDVAD-fmk and the caspase-9 inhibitor Z-LEHD (MBL,
Nagoya, Japan). The cell proliferation assay (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt assay) was performed with a Cell Titer 96
AQueos Cell Proliferation Assay kit (Promega, Madison, WI,
USA) according to the manufacturer’s directions.
In vivo experiments using SCID mice
Five-week-old female C.B-17/Icr-SCID mice obtained from
Ryukyu Biotec (Urasoe, Japan) were maintained in containment
level 2 cabinets and provided with autoclaved food and water ad
libitum. The mice were engrafted with 10
7 HuT102 cells by
subcutaneous injection in the post-auricular region and randomly
placed into two cohorts of ﬁve animals each that received vehicle
or LBH589. Treatment was initiated on the day after cell injection.
LBH589 was dissolved in distilled water at a concentration of
2mg/ml, and 28mg/kg body weight of LBH589 was administered
by oral gavage three times a week. Control mice received the
same volume of the vehicle only. Body weight and tumor numbers
and size were monitored once a week. All mice were sacriﬁced
on day 28, then the tumors were dissected out, and their weight
was measured. After tumors were ﬁxed for parafﬁn embedding
and tissue sectioning, DNA fragmentation was evaluated by
ﬂuorescent TUNEL (TAKARA BIO INC., Shiga, Japan) as recom-
mended by the manufacturer. All these experiments were per-
formed according to the Guidelines for Animal Experimentation
of the University of the Ryukyus and were approved by the
Animal Care and Use Committee of the same university.
Flow cytometric analysis
To evaluate apoptotic changes and the permeability of the
mitochondrial outer membrane, we used an Annexin-V and PI
Kit (Bender Medsystems, Vienna, Austria) and a Mitochondrial
Membrane Potential Assay Kit (5, 50,6 ,6 0-tetrachloro-1, 10,3 ,
30-tetraethylbenzimidazol-carbocyanine iodide detection)
(Cayman Chemical), respectively. Activities of caspase-8 and 9
were determined by ﬂuorometric assay (MBL) according to the
manufacturer’s instructions. The cell-surface expression of death
receptors (DRs), CCR4 and IL-2R was examined by ﬂow cytometric
analysis using anti-tumor necrosis factor-R1 (MBL), anti-CD95 (BD
Biosciences, San Diego, CA, USA), anti-DR5 (Alexis Biochemicals,
San Diego, CA, USA), anti-CCR4 (BD) and anti-CD25 (BD)
monoclonal antibodies. Mouse IgG1 (DAKO, Kyoto, Japan) was
used as a negative control. All experiments were performed using
a FACSCalibur ﬂowcytometer and Cellquest software (BD).
Preparation of whole-cell lysate, nuclear, mitochondrial
and cytosolic fractions
Cells were harvested after treatment and whole-cell lysate
was prepared as described previously.
32 Nuclear extracts from
cells were prepared for NF-kB transcription assays using a
nuclear/cytosol fractionation kit (BioVision, San Diego, CA,
USA), according to the instructions. Similarly, cytosolic fractions
were prepared for western blotting by using a mitochondria/
cytosol fractionation kit (BioVision).
Western blotting, immunoprecipitation and antibodies
Western blotting was performed as described previously.
31 The
analysis was performed using antibodies to p53 (DO-1), MDM2
(Ab-1), FADD, PUMA and NOXA (Merck), phospho-AKT,
AKT, caspase-8, 9 and 3, cleaved caspase-9, cleaved PARP,
BID, BAX, Bcl-xL, cytochrome-c, p21 and acetylated-Lysin (Cell
Signaling Technology, Beverly, MA, USA), p53-induced protein
with a death domain (PIDD) (LifeSpan Biosciences, Seattle, WA,
USA), caspase-2 (11B4) and c-FLIP (Dave-2) (Alexis), RAIDD
and TRADD (MBL), survivin (R&D systems Inc., Minneapolis,
MN, USA), acetylated-histone-H3 and -H4, and Bcl-2 (Upstate
Biotechnology, Waltham, MA, USA), RIP and XIAP (BD), HBZ
(kindly provided by Dr JM Mesnard) and HBZ-SI,
22 Tax,
31
acetylated-tubulin, a-tubulin and b-actin (Sigma Chemicals,
St Louis, MO, USA). In the immunoprecipitation assay, protein
A-Sepharose beads (Sigma), HSP90 antibody (StressGen
Biotechnologies Corporation, Victoria, BC, Canada) and RAIDD
antibody (LifeSpan Biosciences) were used.
Immunohistochemistry
After tumors were ﬁxed for parafﬁn embedding and tissue
sectioning, immunohistochemical staining for acetylated-his-
tone-H3 and -H4 was performed. The deparafﬁnized slides were
pretreated with DAKO Target Retrival Solution (pH 9) (DAKO),
and heated in a water bath at 951C for 40min. For all stains, the
endogenous peroxidase was quenched by 3% H2O2 for 15min.
Sections were then placed in 0.5% nonfat dry milk for 30min
at room temperature. The primary antibodies used were
anti-acetylated-histone-H3 and -H4 (Cell Signaling). They were
allowed to react for 1h at room temperature, and then the
DAKO EnVisionþDual Link System-HRP (DAKO) was applied
using diaminobenzidine as the chromogen, following the
manufacturer’s directions.
Proteasome activity assay
The proteolytic activity of the 20S proteasome was evaluated
with the Biomol AK-740 QuantiZyme Assay System (Biomol)
following the manufacturers’ instructions, which detects the
release of the free 7-amino-4-methylcoumarin ﬂuorophore,
upon cleavage of the ﬂuorogenic peptide Suc-LLVYAMC.
DNA microarray analysis
Total RNA from cells was extracted using ISOGEN (Nippon
Gene, Toyama, Japan) and puriﬁed with a Message Clean kit
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Leukemia(GenHunter Corp., Brookline, MA, USA). The RNA’s integrity
was assessed using an Agilent 2100 Bioanalyzer (Agilent, Palo
Alto, CA, USA). Double-stranded cDNA and biotinylated cRNA
were synthesized using a T7-poly-T primer and the BioArray
RNA labeling kit (Enzo, Farmingdale, NY, USA), respectively.
The labeled RNA was then fragmented and hybridized to
HU-133A oligonucleotide arrays (Affymetrix, Santa Clara, CA,
USA). The arrays were scanned using the Gene Array Scanner
and analyzed using the DNA-Chip Analyzer.
Real-time quantitative RT-PCR
After total RNA was prepared as described above, Real-time
RT-PCR for HBZ, HBZ-SI and Tax were performed using
a LightCycler Technology System (Roche Diagnostics, Basel,
Switzerland) as described previously.
22,28,33 Similarly, PCRs for
caspase-2, caspase-9, RAIDD, PIDD and PBGD were performed
on a Roche LC480 (Roche) with LightCycler 480 Probes Master
mix (Roche) according to the directions. We designed speciﬁc
sets of primers and/or purchased probes as summarized in
Supplementary Table 1.
NF-kB transcription factor assay
Nuclear extracts from cells were prepared as described above.
Activities of NF-kB p50 and p65 were investigated using an
NF-kB transcription factor assay kit (Chemicon, Temecula, CA,
USA) as recommended by the manufacturer.
Transfection, luciferase assay and small interfering
RNA experiments
Transfection was performed with a Cell line Nucleofector kit V
and the Nucleofector system (Lonza, Cologne, Germany). The
transfection programs for ST1 (O-17) and HuT102 (O-16) were
determined so that the viability of cells and the transfection
efﬁciency would be compatible (data not shown). Luciferase
assays using reporter plasmid pG13-Luc were described
previously.
31 The plasmid Myr-AKT (pcDNA3 myr-HA-Akt1)
was obtained from Addgene Inc. (Cambridge, MA, USA).
34
Empty pcDNA3 or Myr-AKT vectors were used for the
AKT-transfection experiment. Cells (5 10
6) were resuspended
in 100ml of Cell line Nucleofector solution V and mixed with
2mg of plasmid DNA. Twenty-four hours after transfection, the
cells were cultured with or without LBH589 and processed for
ﬂow cytometric analysis or western blotting. We prepared three
different small interfering RNA (siRNA) against each target.
Caspase-2: Silencer Select Validated siRNA s2412 (#1), s2410
(#2) and s2411 (#3), caspase-9: Silencer Select siRNA s2430
(#1), s2428 (#2) and s2429 (#3), RAIDD: Silencer Select siRNA
s16656 (#1), s16654 (#2) and s16655 (#3), PIDD: Silencer Select
siRNA s30843 (#1), s30844 (#2) and s226845 (#3), RIP: Silencer
Select Validated siRNA s16651 (#1), s11652 (#2) and s16653
(#3), and control siRNA (Silencer negative control #1) (Applied
Biosystems, Foster City, CA, USA). After evaluating the effect of
each siRNA by monitoring the target’s mRNA and protein
(Supplementary Figure 2), we eventually selected a set of #1
siRNA against each target. Cells were used 24h after transfec-
tion and each siRNA experiment was performed in triplicate.
Results
LBH589 causes acetylation of histones and non-histone
proteins in ATLL cells
Hydroxamate-based DACi including LBH589 induce hyper-
acetylation of histones H3/H4 and a-tubulin.
2,4 Recent reports
also indicated that LAQ824 and LBH589 can cause acetylation
of HSP90 and the disruption of its chaperone function, resulting
in repression of HSP90 client proteins including AKT.
12,35 We
ﬁrst conﬁrmed that LBH589 was very effective in increasing the
acetylation of histones H3/H4 and a-tubulin in ATLL-related cell
lines (Figure 1a). As expected, LBH589 also caused acetylation
of HSP90 in ST1, KOB and KK1 cells and signiﬁcantly reduced
the expression of phospho-AKT (Figures 1b and c).
LBH589 induces apoptosis in ATLL cells
Next, we examined the effect of LBH589 on the growth of 8
ATLL-related cell lines, Jurkat cells and K562 cells. LBH589
caused B60% inhibition of cell growth at a concentration of
25nM in the ATLL-related cell lines and Jurkat cells, and about
30% inhibition in the K562 cells (Figure 2a). ST1, HuT102 and
MT2 cells were especially sensitive with more than 60% of their
growth inhibited at 12nM. To determine the details of LBH589-
mediated cell death, we performed Annexin-V/PI staining. After
48-h treatment with 25nM of LBH589, Annexin-V-positive cells
in the ST1 and HuT102 cell lines increased from 8 and 4% to
71 and 92%, respectively (Figure 2b). Likewise, more than 30%
of cells were positive for Annexin-V after 24-h treatment with
25nM of LBH589 in the other cell lines except K562, in which
the proportion was 9.5% (Figure 2c). These results indicate that
ATLL-related cell lines are highly sensitive to LBH589-induced
apoptosis. Similar to the results for the cell lines, LBH589
signiﬁcantly inhibited cell proliferation in all primary ATLL cell
samples examined. In contrast, normal peripheral blood mono-
nuclear cells were less harmed than ATLL cells (Figure 2d).
Annexin-V/PI staining conﬁrmed that LBH589 induces apoptotic
cell death in primary ATLL cell samples (Figure 2e).
Treatment of subcutaneous tumors with LBH589
We examined whether LBH589 is also effective against ATLL cells
in the in vivo setting, by using SCID mice transplanted with
HuT102 cells. Ten mice were inoculated, ﬁve of which were
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Figure 1 LBH589 causes acetylation of histones and non-histone
proteins in adult T-cell leukemia/lymphoma (ATLL) cells. Cells were
treated with either vehicle or the indicated concentrations of LBH589
for 24h. Whole-cell lysate was prepared, and (a and c) western
blotting was performed. (b) For each sample, 100mg of cell lysate was
used for immunoprecipitation with a monoclonal antibody to heat
shock protein 90kDa a (HSP-90), and western blotting was performed.
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Leukemiatreated with LBH589 and ﬁve of which were left untreated.
LBH589 reduced the volume of tumors more than 70% (Figure 3a).
The mean tumor weight of LBH589-treated mice was signiﬁcantly
lower than that of control mice (Figure 3b). Immunohistochemical
staining conﬁrmed that LBH589 was very effective in increasing
the acetylation of histones H3/H4 in tumors of treated mice
(Figure 3c). We further conﬁrmed by a TUNEL assay that LBH589
caused evident apoptosis in transplanted tumors (Figure 3d).
Analysis of the extrinsic pathway in LBH589-induced
apoptosis
DACi are reported to activate the extrinsic pathway, in many
cases, in cooperation with (DRs).
2 Among typical DRs, DR5 was
expressed in ATLL-related cell lines
28 but tumor necrosis factor-
R1 mostly was not (not shown) and there was no change
after LBH589 treatment (not shown). LBH589 rather reduced Fas
expression in ST1, LMY1 and HuT102 cells (Figure 4a). In
typical DR-mediated apoptosis (JurkatþTRAIL), both extrinsic
and intrinsic pathways are activated including cleavage of BID,
which was not observed in K562 cells treated with 12nM of
LBH589 (Figure 4c). In ATLL cell lines, western blotting revealed
no bands of cleaved caspase-8 on treatment with LBH589
(Figure 4b). This was accompanied by slight changes in FADD
and BID expression (Figure 4b). In contrast, LBH589 reduced the
expression of FLIP proteins in HuT102 and KK1 cells (Figure 4b).
Fluorometric analysis eventually showed that LBH589 little
0
20
40
60
80
100
120
01 2 2 5 5 0
LBH589 concentrations (nM) 
c
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
ANNEXIN-V
P
I
LBH589 ( 50nM )
ATL case 6 ATL case 4-1
LBH589 ( 25nM )
0 24 48 0 24 0 24
LBH589 ( 25nM )
ATL case 8
36 43 3 96 33 45 30
3.3
63 1.2 93
2.2
94 1.6 26 19
52 20 0.2 21 2.6
ATL3
ATL2
ATL1
ATL4-1
ATL7
ATL4-2
ATL5
ATL6
ATL8
Normal-1
Normal-2
(hours)
0
20
40
60
80
100
120
036 1 2 2 5 5 0
LBH589 concentrations (nM) 
ST1
KK1
KOB
SO4
Jurkat
K562
HuT102
LM-Y1
LM-Y2
MT2
c
e
l
l
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
0
10
20
30
40
50
60
LBH589 (nM)
0 6 12 25 50
Annexin-V-positive cells (%)
ST1
KK1
KOB
SO4
K562
HuT102
LM-Y1
MT2
P
I
ANNEXIN-V
S
T
1
 
92
3.5
LBH589 ( 25nM )
0
28
43
H
u
T
1
0
2
2.1
95 2.3 6.0 70
22
28 4.4
48  (hours)
Figure 2 LBH589 induces apoptosis in adult T-cell leukemia/lymphoma (ATLL)-related cell lines and primary ATLL cells. (a and d) Cell lines
(3–5 10
5/ml), primary ATLL cells or normal peripheral blood mononuclear cell (PBMCs) (7–10 10
5/ml) were treated with either vehicle or
the indicated concentrations of LBH589 for 48h and cell proliferation (% against cells cultured without LBH589) was evaluated by MTS (3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay. (b, c and e) After cells were treated with
the indicated concentrations and time course, Annexin-V/PI staining was performed. (b and e) Percentages of intact cells (Annexin-V
  PI
 ), early
apoptotic cells (Annexin-V
þ PI
 ) and late apoptotic or necrotic cells (Annexin-V
þ PI
þ) are indicated in the lower panels. (c) Percentages of
Annexin-V-positive cells were evaluated. (a, c and d) Experiments were performed in triplicate and results were expressed as the mean±s.d. In
ATLL case 4, samples from peripheral blood mononuclear cells (4–1) and pleural effusion (4–2) were investigated.
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Leukemiaactivated caspase-8 in ATLL-related cell lines in contrast to
caspase-9 (Figure 4d). These results suggest that LBH589 does
not activate the extrinsic pathway in ATLL-related cell lines.
LBH589 induces apoptosis in ATLL cells by activating
the intrinsic pathway
Next, we investigated the changes in permeability of the mito-
chondrial membrane in cells treated with LBH589 by using
the 5, 50,6 ,6 0-tetrachloro-1, 10,3 ,3 0-tetraethylbenzimidazol-
carbocyanine iodide dye. The percentage of cells with
decreased red ﬂuorescence was increased from 7.3 to 81%
and from 11 to 76% in ST1 and HuT102 cells, respectively
(Figure 4e). Time course analyses of these changes are shown in
Figure 4f. Furthermore, the release of cytochrome-C from
mitochondria to the cytosol was detected by western blotting
(Figure 4g). The activation of caspase-9 was conﬁrmed by the
appearance of cleaved caspase-9 and by a ﬂuorometric analysis,
which showed a three–eightfold increase after treatment with
LBH589 (Figures 4b and d). The bands of cleaved caspase-3 and
cleaved PARP, as a result of apoptosis, were clearly observed
(Figure 4b). Collectively, these results suggest that the major
mechanism of LBH589-induced apoptosis is activation of the
intrinsic pathway.
Contribution of caspase-9 and/or AKT in
LBH589-induced apoptosis
Interestingly, the band for pro-caspase-9 did not decrease in
intensity in spite of its consumption but rather increased on
treatment with LBH589 (Figure 4b). AKT has been shown to
downregulate the expression of caspase-9 via direct phosphor-
ylation
36 and LBH589 signiﬁcantly reduced the expression of
phospho-AKT (Figure 1c). Then, we used a typical PI3K/AKT
inhibitor, LY294002, to investigate the impact of AKT’s
inactivation in LBH-induced apoptosis. ATLL cell lines with
phospho-AKT actually underwent apoptosis and showed a
decrease in phospho-AKT on treatment with LY294002. In this
setting, however, the expression of caspase-9 was not upregu-
lated (not shown). Furthermore, we performed transfection
experiments with myr-AKT. The expression levels of phospho-
AKT were not decreased by LBH589 in myr-AKT-transfected
HuT102 cells (Supplementary Figure 1B). In this setting, we
found that the percentage of Annexin-V-positive cells was
decreased in myr-AKT cells (Supplementary Figure 1A). Expres-
sion levels of cleaved caspase-3 in LBH589-treated myr-AKT
cells were moderately lower than those in mock-transfected
cells (Supplementary Figure 1B). However, expression levels
of other key molecules including caspase-9 were not altered
(Supplementary Figure 1B). These results suggest that the LBH589-
induced decrease in phospho-Akt levels is not an event upstream
of the LBH589-induced accumulation of caspase-9 but partly
contributes to the pro-apoptotic effects of LBH589.
Microarray analysis
We performed a DNA microarray analysis using HuT102 and
LM-Y1 cells and compared gene expression proﬁles between
cells treated with LBH589 and cells left untreated focusing on
how the intrinsic pathway is activated during LBH589-induced
apoptosis (Table 1). Among commonly observed changes, an
upregulation of cytochrome-C expression and a downregulation
of p53 expression were remarkable. An upregulation of
caspase-9 expression and a downregulation of FAS expression,
were in accord with results of western blotting and ﬂow
cytometric analysis, respectively (Figures 4a and b). Taking into
consideration the results of the microarray analysis, we
performed further studies focusing on three different groups;
ATLL-characteristic, p53-related and caspase-2-related proteins.
Analysis of proteins characteristic of ATLL cells
We ﬁrst focused on CCR4 and IL-2R, which were remarkably
affected by LBH589 (Table 1). A majority of ATLL cells
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Figure 3 LBH589 reduces tumors inoculated in SCID mice. HuT102
cells (10
7 per mouse) were injected subcutaneously into SCID mice.
The mice (ﬁve per group) were treated with either vehicle or LBH589.
Treatment was initiated on the day after inoculation. Tumor volume
and weight were monitored on the indicated days after the injection of
cells. (a) Serial changes in tumor volume in treated and untreated
mice. Data are the mean±s.d. for ﬁve mice each. Mann–Whitney’s
U-test was used to compare results with control values. (b) Tumors
removed from untreated mice and LBH589-treated mice on day 28
after cell inoculation were weighed. (c) Immunohistochemical staining
shows the acetylation of histones H3/H4 in tumors of treated mice.
(d) TUNEL assays show apoptotic cells in tumors from mice treated
with LBH589 compared with the control mice. Magniﬁcation,  40.
LBH589 induces apoptosis in ATLL cells
H Hasegawa et al
579
Leukemiaconsistently express CCR4, which contributes to tumor cell
progression and/or invasion.
37 ATLL-related cell lines had high
levels of CCR4, which were dramatically decreased by LBH589
treatment (Figure 5a). IL-2R is also known to be overexpressed in
ATLL cells and is often used as a diagnostic marker for ATLL.
17
LBH589 repressed the expression of IL-2R B50% in the
ATLL-related cell lines though levels were still extremely high
(Figure 5b). Importantly, IL-2R is a typical gene whose promoter
is activated by HTLV-1 Tax. Then, we investigated whether the
expression of Tax mRNA is also affected by LBH589. The effect
depended on the cells examined. In cells with high Tax mRNA
levels (KOB, MT2 and HuT102), the expression tended to
increase with LBH589 treatment, while in cells with relatively
low Tax mRNA levels (LMY1, KK1 ST1 and SO4), it tended to
decrease (Figure 5c). These results were consistent with those of
western blotting (Figure 5c upper panel). The behavior of the
HBZ mRNA was similar to that of the Tax mRNA; cells with high
Tax levels tended to show an increase in HBZ mRNA on
LBH589 treatment, while cells with lower Tax levels tended to
exhibit a decrease (Figure 5d). In contrast, LBH589 signiﬁcantly
repressed HBZ-SI mRNA expression in ATLL-related cell lines
except MT2 cells (Figure 5e). Protein levels of HBZ and HBZ-SI
were not high in any cells examined and the expression proﬁles
were approximately the same as those for the mRNA (Figures
5d and e). As NF-kB is constitutively activated in ATLL cells
dependent on and/or independent of HTLV-1 Tax
38,39 and the
repression of NF-kB is an important mechanism in DACi-
induced ATLL cell death,
40,41 we examined the activities of
NF-kB. However, repression of NF-kB by LBH589 was not
commonly observed in ATLL-related cell lines (not shown).
LBH589-induced apoptosis in ATLL cells does not
depend on the p53 pathway
Although p53 is an important inducer of the intrinsic apoptotic
pathway, its gene expression was signiﬁcantly decreased by
LBH589 treatment (Table 1). To verify this phenomenon, we
performed a luciferase assay with pG13-Luc using ST1, HuT102,
KOB and KK1 cells and found that activation of p53 had
not occurred (not shown). Unexpectedly, LBH589 reduced the
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Figure 4 Analysis of the apoptotic pathway in LBH589-induced cell death. Cells were treated with either vehicle or the indicated concentrations
of LBH589 for 24–48h. After cells were harvested, ﬂow cytometric analysis (FCM) (a, d, e and f) or western blotting (b and g) was performed.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (100ng/ml)-treated Jurkat cells were used as a positive control of typical apoptosis
and LBH589 (12nM)-treated K562 cells were used as a negative control (c, d and f). (a) Changes in expression of Fas were indicated using RFI
(the ratio of mean ﬂuorescence intensity for speciﬁc staining to that for control staining). (d) Activities of caspases. Cells were incubated with the
IETD-FMK for caspase-8, conjugated to FITC (FITC-IETD-FMK) or the LEHD-FMK for caspase-9, conjugated to FITC (FITC-LEHD-FMK) and
analyzed using FCM. Comparison of the ﬂuorescence intensity in the treated sample with that of the untreated control allows determination of the
fold increase in activity of each caspase. (e and f) Mitochondrial membrane permeability. Cells were incubated with the JC-1 dye and analyzed
using FCM. The percentage of cells with low JC-1 red ﬂuorescence was evaluated. (b, c and g) Western blotting was performed using whole-cell
lysate (b and c) or a cytosolic fraction (g) prepared as described in Materials and methods.
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LeukemiaTable 1 Microarray analysis of HuT102 cells
Symbol Gene Fold change
HuT102 LM-Y1
SPP1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation-1) 6.4 9.4
DHRS2 Dehydrogenase/reductase (SDR family) member-2 6.2 2.5
SERPINB2 Serpin peptidase inhibitor, clade B (ovalbumin), member-2 5.6 3.8
CASP9 Caspase 9, apoptosis-related cysteine peptidase 3.9 1.7
BTG2 BTG family, member-2 3.4 2.2
CYCS Cytochrome-C, somatic 3.4 2.1
CLU Clusterin 3.1 2.1
CTSB Cathepsin B 3.1 3.5
GADD45B Growth arrest and DNA damage inducible, beta 2.9 3.6
PHLDA1 Pleckstrin homology-like domain, family A, member-1 2.9 2.0
EFHC1 EF-hand domain (C-terminal) containing 1 2.8 2.6
IFI6 Interferon, alpha-inducible protein 6 2.7 2.2
NLRP1 NLR family, pyrin domain containing 1 2.7 1.1
LOH11CR2A Loss of heterozygosity, 11, chromosomal region 2, gene A 2.6 2.3
RARRES3 Retinoic acid receptor responder (tazarotene induced) 3 2.5 2.5
ARHGAP20 Rho GTPase activating protein 20 2.3 1.7
BCL10 B-cell CLL/lymphoma 10 2.3 1.5
BTG1 B-cell translocation gene 1, anti-proliferative 2.3 1.4
ACVR1C Activin A receptor, type IC 2.2 1.0
FASLG Fas ligand (TNF superfamily, member-6) 2.2 F
RECK Reversion-inducing-cysteine-rich protein with kazal motifs 2.2 F
SIAH2 Seven in absentia homolog 2 (Drosophia)2 . 2 F
APAF1 Apoptotic peptidase-activating factor-1 2.1 1.5
ATM Ataxia telangiectasia mutated (includes complementation groups A, C and D) 2.1 F
CRADD CASP2 and RIPK1 domain containing adaptor with death domain 2.1 1.6
RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase-1 2.1 1.3
LTA Lymphotoxin alpha (TNF superfamily, member-1)  6.1 F
IL10 Interleukin-10  4.4 F
TNFRSF8 Tumor necrosis factor receptor superfamily, member-8  4.2 F
CCR4 Chemokine (C-C motif) receptor 4  3.8  2.6
IL2RA Interleukin-2 receptor, alpha  3.8  2.6
TP53 Tumor protein p53 (Li-Fraumeni syndrome)  3.5  1.5
IKZF1 IKAROS family zinc ﬁnger-1 (Ikaros)  3.4  2.1
CCNB1 Cyclin B1  3.3  3.8
FAS Fas (TNF receptor superfamily, member-6)  3.3  1.6
MKI67 Antigen identiﬁed by monoclonal antibody Ki-67  3.2  4.4
CDC2 Cell division cycle 2, G1 to S and G2 to M  3.2 F
PLK1 Polo-like kinase 1 (Drosophila)  3.0  1.4
SULF1 Sulfatase 1  3.0 F
BIRC5 Baculoviral IAP repeat-containing 5 (survivin)  2.9  3.8
CDK2AP1 CDK2-associated protein-1  2.9  1.1
AVEN Apoptosis, caspase activation inhibitor  2.8 F
MCM5 Minichromosome maintenance complex component-5  2.8  3.5
CDC25A Cell division cycle 25 homolog A (Schizosaccharomyces pombe)  2.7  4.0
MYBL2 v-myb Myeloblastosis viral oncogene homolog (avian)-like-2  2.7  4.0
MYC v-myc Myelocytomatosis viral oncogene homolog (avian)  2.7  1.9
BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)  2.6  4.1
CDCA3 Cell division cycle associated-3  2.6  3.5
FAIM Fas apoptotic inhibitory molecule  2.6  2.1
ATF5 Activating transcription factor-5  2.5  3.3
WEE1 WEE1 homolog (Schizosaccharomyces pombe)  2.5  2.8
BCAT1 Branched chain aminotransferase 1, cytosolic  2.4  2.1
CCNA2 Cyclin A2  2.4  3.8
STEAP3 STEAP family member 3  2.4  1.3
ZAK Sterile alpha motif and leucine zipper containing kinase AZK  2.4  3.2
CCNB2 Cyclin B2  2.3  3.8
FBXO5 F-box protein-5  2.3  2.6
HMGB1 High-mobility group box 1  2.3  2.7
NEK6 NIMA (never in mitosis gene a)-related kinase-6  2.3  3.2
RYR1 Ryanodine receptor 1 (skeletal)  2.3 F
SFRS2 Splicing factor, arginine/serine-rich-2  2.3  1.7
AURKA Aurora kinase A  2.2  3.0
BCLAF1 BCL2-associated transcription factor 1  2.2  1.9
CXCR4 Chemokine (C-X-C motif) receptor-4  2.2  1.7
E2F8 E2F transcription factor-8  2.2  3.4
CDC45L CDC45 cell division cycle 45-like (S. cerevisiae)  2.1  4.3
CSE1L CSE1 chromosome segregation 1-like (yeast)  2.1  1.8
HK2 Hexokinase-2  2.1 F
NME1 Non-metastatic cells 1, protein (NM23A) expressed in  2.1  1.3
Abbreviation: TNF, tumor necrosis factor. HuT102 and LM-Y1 cells were treated with either vehicle or 50nM of LBH589 for 24h and DNA
microarray analyses were performed. Among genes with changes in expression of at least 2.1-fold (log 2 ratio) in either direction in HuT102 cells,
we picked those with known functions related to apoptosis, the cell cycle and cell proliferation.
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Leukemiaexpression of p53 in ST1 and KK1 as well as HuT102 cells
without any accumulation of MDM2, which degrades p53
(Figure 6a). In contrast, the band of p21 was increased
in intensity in these cell lines irrespective of their p53 status.
Among apoptosis-related proteins downstream of p53, we found
an increase in survivin, a decrease in XIAP, and no change in
BAX, PUMA and Bcl-2 on treatment with LBH589 in ST1 or
HuT102 cells. These results suggest that typical Bcl-2 family
members are not involved in the permeabilization of the
mitochondrial membrane in LBH589-induced apoptosis. Inter-
estingly, LBH589 increased the expression of Bax and PUMA
and decreased that of Bcl-2 and Bcl-xL in KK1 cells carrying
a non-functional p53 mutation. These results indicate that
LBH589 induced apoptosis in ATLL-related cell lines in a
p53-independent manner.
Analysis of caspase-2-related apoptotic pathway
CASP2 and RIPK1 domain containing adaptor with death
domain (also known as RAIDD), RIP, caspase-9 and cyto-
chrome-C are involved in caspase-2-mediated apoptosis and
were upregulated in their expression after LBH589 treatment
(Table 1). The apoptosis induced by tumor necrosis factor-R1
requires the adaptor proteins TRADD, RIP and RAIDD in
addition to caspase-2.
42 Recent reports suggest that caspase-2
can cause cytochrome-C’s release from mitochondria directly or
indirectly.
43,44 Additionally, PIDD can interact with RAIDD and
caspase-2, forming a PIDDosome and inducing apoptosis.
45 We
investigated the expression proﬁles of caspase-2-related proteins
by western blotting (Figures 6b and c). Caspase-2 was clearly
activated by the treatment with LBH589 and cleaved forms were
observed. Similar results were observed in TRAIL-treated Jurkat
cells (Figure 6c). PIDD (90kDa) is constitutively processed into
51 and 37kDa forms and cleaved PIDD (37kDa) is essential for
the activation of caspase-2.
46 Furthermore, upregulation of the
expression of general forms of PIDD was observed during the
activation of caspase-2 induced by genotoxic agents.
46 ATLL
cell lines and Jurkat cells expressed various forms of PIDD,
levels of which were not increased by LBH589 or TRAIL (Figures
6b and c). RIP was increased and TRADD was decreased in KK1
cells but neither was changed in ST1 or HuT102 cells. Of note,
the activation of RAIDD was a common characteristic in these
cells. Furthermore, the activation of RAIDD was also observed
at the mRNA level in most of the ATLL-related cell lines
(Figure 6d). In KK1 and ST1 cells, the activation of RAIDD
mRNA expression was faint whereas that of protein production
was obvious. We analyzed the 20s proteasome’s activities to
investigate whether RAIDD regulation by LBH589 in these cells
is due to proteasome inhibition (Supplementary Figure 1C).
Activities of 20S proteasome were dramatically impaired by
MG132 in all cells examined and were not changed by LBH589
in KK1 and ST1 cells. The expression of RAIDD mRNA was not
induced by the various chemicals used except LBH589
(Figure 6d, Supplementary Figure 1C, and data not shown).
These results suggest that LBH589 caused the activation of
caspase-2 and RAIDD without activating p53 and PIDD. We
further observed the activation of RAIDD and caspase-2 in
addition to acetylated histones in primary ATLL cells (Figure 6e).
LBH589 induces apoptosis in ATLL cells via caspase-2’s
activation
To further investigate the role of caspase-2-mediated apoptosis
in LBH589-induced cell death, we ﬁrst performed inhibition
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Figure 5 Effect of LBH589 on proteins characteristic of adult T-cell leukemia/lymphoma (ATLL) cells. Cells were treated with either vehicle or
50nM of LBH589 for 24h. After cells were harvested, ﬂow cytometric analysis (FCM), real time quantitative RT-PCR and western blotting were
performed. (a and b) Changes in expression of CCR4 and IL-2R were evaluated by FCM. The results were indicated using RFI. (c–e) Real-time
quantitative RT-PCR and western blotting against HTLV-1 Tax, HBZ and HBZ-SI were performed as described in materials and methods. RT-PCRs
were carried out in duplicate and the average value was used as the absolute amount of each mRNA. The cells were divided into three groups
according to the amount of Tax mRNA; cell lines with high Tax mRNA levels (KOB, MT2 and HuT102), moderate levels (LM-Y1) and low levels
(KK1 ST1 and SO4). The results of western blotting are also shown in each panel. (b–e) Results were expressed as the mean±s.d. for three
independent experiments and were also analyzed using Student’s t-test. *Po0.01.
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Leukemiaassays of caspases using speciﬁc inhibitors. The proportion of
Annexin-V-positive cells among TRAIL-treated Jurkat cells was
reduced from 67 to 20% by the pan-caspase inhibitor Z-VAD
(Figure 7a). LBH589-induced cell death was also attenuated by
Z-VAD with the percentage of Annexin-V-positive cells decreas-
ing from 47 and 54% to 16 and 21% in ST1 and HuT102 cells,
respectively. The caspase-8 inhibitor was not effective against
LBH589-induced cell death, consistent with the ﬁnding
that caspase-8 was not activated (Figure 4d). Importantly, the
caspase-2 inhibitor Z-VDVAD had a similar effect to Z-VAD
in LBH589-treated Jurkat cells, while it had a weak effect in
TRAIL-treated cells (46%). Furthermore, western blotting
revealed that the cleavage of caspase-3 by LBH589 was
inhibited by Z-VDVAD as well as Z-VAD (not shown). These
results suggest that LBH589 causes apoptosis in ATLL-related
cell lines in a caspase-dependent manner and activation of
caspase-2 is essential.
RAIDD as well as caspase-2 has a critical role in
LBH589-induced apoptosis
Next, we performed siRNA experiments targeting caspase-2,
caspase-9, RAIDD, PIDD and RIP to disclose the key triggers of
apoptosis. Annexin-V/PI assays revealed that siRNA of
RAIDD signiﬁcantly repressed LBH-induced cell death, as did
si-caspase-2 (Figure 7b). The proportion of Annexin-V-positive
cells was B65% in si-control cells and 37% in ST1 si-RAIDD
cells. Similar results were obtained with HuT102 cells using
siRNA set #1 (Figure 7b), set #2, and set #3 (Supplementary
Figure 2C and E). Si-caspase-9 also inhibited LBH589-induced
cell death while si-PIDD and si-RIP caused no change
(Figure 7b). Similar inhibitory effects by si-RAIDD and
si-caspase-2 were observed in JC-1 experiments (Figure 7c).
The effect of si-caspase-9 was less extensive than that of si-PIDD
or si-RIP (Figure 7c). These results suggest that RAIDD as well as
caspase-2 has a critical role in LBH589-induced apoptosis
and, importantly, they have active roles upstream of the
mitochondria.
RAIDD has an initiating role in LBH589-induced
apoptosis
Western blotting revealed that si-caspase-2 suppressed the
cleavage of caspase-9, caspase-3 and PARP as well as the
expression of caspase-2 itself. However, it could not suppress
the activation of RAIDD (Figure 7d). Si-caspase-9 suppressed the
cleavage of caspase-3 and PARP as well as the expression
of caspase-9 itself, but could not suppress the activation of
caspase-2 or RAIDD. Of note, si-RAIDD most effectively
suppressed the cleavage of caspase-2, caspase-9, caspase-3
and PARP as well as the upregulation of RAIDD expression.
Si-PIDD and si-RIP did not alter the expression proﬁles of
caspases and RAIDD. These changes were basically similar in
ST1 and HuT102 cells. An additional siRNA experiment was
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Figure 6 LBH589 activates RAIDD and caspase-2, but not p53. Whether the p53 pathway or caspase-2-related factors contribute to the LBH589-
induced cell death was investigated by using ST1 and HuT102 (p53 wild type) cells, and KK1 (p53 mutated) cells. (a, b and e) Cells were treated
with either vehicle or the indicated concentrations of LBH589 for 24h. After cells were harvested, western blotting was performed. (c) Western
blotting: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (100ng/ml)-treated Jurkat cells were used as a positive control of typical
apoptosis and LBH589 (12nM)-treated K562 cells were used as a negative control. (d) Activation of RAIDD by LBH589. After cells were treated
with either vehicle or 50nM of LBH589 for 24h, real-time quantitative RT-PCR for RAIDD was performed. The fold increase in each cell line was
obtained by setting the value for the expression without LBH589 as 1.0.
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Leukemiaperformed using set #2 and set #3 siRNAs and results were
similar to Figure 7d (Supplementary Figure 2D and F). The
results indicate that the activation of RAIDD occurs upstream of
the activation of caspase-2 and has an initiating role in LBH589-
induced apoptosis.
Discussion
DACi achieved signiﬁcant biological effects in preclinical
models of cancer including hematological malignancies which
has led to clinical trials.
4,47–49 Then, it has become important to
re-evaluate the mechanisms of tumor cell death caused by
DACi. These processes will improve the design of further
clinical trials and help in developing novel DACi. In this study,
we showed that a newly developed DACi, LBH589, effectively
induces ATLL cell death both in vitro and in vivo by a unique
mechanism that has not been reported. Our ﬁndings uncovered
a new role of caspase-2’s activation in the induction of
apoptosis.
It has been recognized that caspase-2-mediated apoptosis is
initiated by death receptors.
42,50 However, recent studies
revealed the ability of caspase-2 to engage the intrinsic pathway
in response to DNA damage.
43,51–53 One possibility is that
caspase-2 acts indirectly on the mitochondria, by cleaving the
pro-apoptotic protein BID or by activating Bax and inducing the
release of cytochrome-C.
44 Another alternative is that caspase-2
directly permeabilizes the mitochondrial membrane and stimu-
lates the release of cytochrome-C independently of the Bcl-2
family including Bax and Bcl-2.
54 In addition, a recent report
indicated that caspase-2 became activated in the so called
PIDDosome, a complex of PIDD, caspase-2 and RAIDD, in a
p53-dependent manner.
45 In our study, si-caspase-2 and
si-RAIDD inhibited LBH589-induced apoptosis as well as
permeabilization of the mitochondrial membrane. This mechan-
ism is similar to the PIDDosome, however, LBH589-induced
apoptosis was independent of p53 and PIDD was not activated.
In addition, si-PIDD or si-RIP did not alter LBH589-induced
apoptosis. Si-caspase-2 could not suppress the activation of
RAIDD while si-RAIDD effectively suppressed the cleavage of
caspase-2. These results indicated that LBH589 caused the
activation of caspase-2 followed by RAIDD independent of p53
and PIDD. Regarding this point, a previous report suggested that
caspase-2’s activation occurred in a p53-independent manner.
55
Furthermore, two recent studies using PIDD-deﬁcient mice
demonstrated the PIDDosome-independent activation of cas-
pase-2.
56,57 From our results, si-caspase-2 attenuated the
LBH589-induced permeabilization of the mitochondrial mem-
brane and the mRNA expression of cytochrome-C was highly
upregulated by LBH589 probably due to cytochrome-C’s
release. In contrast, most of the Bcl-2 family proteins were not
altered by LBH589. In this regard, Robertson et al. suggested
that caspase-2 can directly stimulate the intrinsic pathway
independent of the Bcl-2 family.
43 More recently, Sidi et al.
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Figure 7 RAIDD has a critical role in initiating LBH589-induced
apoptosis. (a) Inhibition assay of caspases. Cells were treated with
25nM of LBH589 or 100ng/ml of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) with indicated concentrations of
caspase-inhibitors for 24h. Results were evaluated by Annexin-V/PI
staining. Experiments were performed in triplicate and results were
expressed as the mean±s.d. (b and c) Effects of siRNA against
caspase-2, caspase-9, RAIDD, PIDD and RIP. At 24h after transfec-
tion, cells were incubated for 24h with either vehicle or 50nM
of LBH589. Results were evaluated using Annexin-V/PI staining or the
JC-1 dye and analyzed with ﬂow cytometric analysis. Results were
expressed as the mean±s.d. for three independent experiments and
were also analyzed using Student’s t-test. *Po0.01 compared with
si-control. (d) Western blotting. At 24h after transfection, cells were
incubated for 24h with either vehicle or 50nM of LBH589 and western
blotting was performed.
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that bypasses a deﬁciency of p53 and excess of Bcl-2.
58 These
reports are partly consistent with our own observations.
However, our scenario does not work without the activation
of RAIDD. Therefore, our results suggest that ATLL cells make
use of a unique RAIDD-caspase-2-induced intrinsic pathway,
which has not been reported previously. Additionally, as
caspase-2-mediated apoptosis requires caspase-9,
51 upregula-
tion of caspase-9 expression by LBH589 is advantageous to the
induction of apoptosis. Although a number of independent
studies strongly support a role for the intrinsic pathway in
DACi-induced apoptosis, the mechanism remains to be fully
elucidated.
1 Our ﬁndings may provide some explanation.
Although there is a consensus that the p53 pathway is
inactivated by Tax in ATLL cells,
59 we recently found that
ATLL-related cell lines expressing the wild-type p53 harbor an
intact p53 pathway.
31 Some previous ﬁndings highlighted the
importance of p53 in the effect of DACi, however, other
studies demonstrated that the expression of wild-type p53 is not
necessary for DACi-induced apoptosis.
2,60,61 Meanwhile, it has
been reported that p21, downstream of p53, is activated by
DACi independent of p53.
62,63 Indeed, the expression of p21
was increased by LBH589 in ATLL-related cell lines irrespective
of their p53 status. In the present study, we clearly showed that
LBH589 does not activate p53 in ATLL-related cell lines with the
wild-type p53, and LBH589 was also effective against p53-
mutant cells via the induction of a p53-like pro-apoptotic
response. A similar phenomenon was reported previously in that
the DACi FR901228 caused a p53-like pro-apoptotic response
in p53 mutant cells and the degradation of the mutant p53
protein.
64 We further conﬁrmed that LBH589 caused the
degradation of p53 protein in p53 wild-type cells as well as
p53-mutant cells. These results suggest that some types of DACi
including LBH589 act upstream of the p53 pathway and cause
the degradation of even mutated p53 protein via an unknown
mechanism.
We also explored the ATLL-speciﬁc mechanisms in LBH589-
induced cell death. Notably, CCR4 and IL-2R, well-known
molecular targets in ATLL therapy, were repressed by the
LBH589 treatment.
65,66 We speculated that Tax participates in
the suppression of IL-2R, however, cells with high Tax mRNA
levels actually showed an increase in Tax mRNA expression
after LBH589 treatment. These results indicate that LBH589 can
cause apoptosis even in Tax-expressing ATLL cells. In our study,
mRNA levels of Tax and HBZ in ATLL-related cell lines were not
inversely correlated. In addition, after treatment with LBH589,
mRNA levels of Tax and HBZ changed in parallel. These results
are not consistent with the idea that HBZ can inhibit Tax’s
activation.
19 Meanwhile, the expression of HBZ-SI was
suppressed by LBH589 in most of the ATLL-related cell lines.
Although the precise function of HBZ-SI is still under investiga-
tion,
24 a previous study found that inhibition of HBZ-SI by
shRNA resulted in cell growth inhibition in ATLL cells.
23 Thus,
HBZ-SI could potentially be a molecular target in ATLL therapy
and the decrease in HBZ-SI caused by LBH589 treatment may
also contribute to the apoptosis of ATLL cells. Consequently,
we demonstrated that LBH589 is a promising drug against ATLL,
and also identiﬁed a novel intrinsic pathway in LBH589-
induced apoptosis.
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